Clinical Trials
110 trialsNCT07099898 2026-05-27
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Phase 3 Recruiting
NCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06612151 2026-05-26
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Active not recruiting
NCT07005128 2026-05-22
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT06992609 2026-05-20
ALBORAN
AstraZeneca
Phase 3 Recruiting
NCT07218146 2026-05-14
DLLEVATE
Zai Lab (Hong Kong), Ltd.
Phase 3 Recruiting
NCT05153239 2026-05-13
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
Phase 3 Completed
NCT07472517 2026-05-12
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Recruiting
NCT06646276 2026-05-11
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT04804644 2026-05-04
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NRG Oncology
Phase 3 Recruiting
NCT06117774 2026-04-29
DeLLphi-306
Amgen
Phase 3 Active not recruiting
NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
NCT07502300 2026-04-20
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06500026 2026-04-17
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT06840704 2026-04-02
Relief
Hunan Cancer Hospital
Phase 3 Recruiting
NCT07015892 2026-03-31
ESCALADOR
Instituto de Investigación Biomédica de Salamanca
Phase 3 Recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07010263 2026-03-05
AK112-311
Akeso
Phase 3 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT04665856 2026-02-13
SKYSCRAPER-02C
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06712355 2026-02-13
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05353257 2026-01-13
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 3 Active not recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT07189455 2026-01-05
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Recruiting
NCT06211036 2025-12-17
DeLLphi-305
Amgen
Phase 3 Active not recruiting
NCT04063163 2025-12-09
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Completed
NCT03703297 2025-11-21
ADRIATIC
AstraZeneca
Phase 3 Active not recruiting
NCT06457906 2025-07-16
SHARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT05224141 2025-07-08
KEYVIBE-008
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06954246 2025-06-18
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04155034 2025-05-25
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04774380 2025-05-23
LUMINANCE
AstraZeneca
Phase 3 Completed
NCT06961201 2025-05-07
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT06789796 2025-02-11
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT02349412 2025-02-07
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT04012606 2025-01-16
Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT04830813 2024-12-09
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT06719336 2024-12-05
Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)
Peking University Cancer Hospital & Institute
Phase 3 Not yet recruiting
NCT05566041 2024-10-31
REPLATINUM
EpicentRx, Inc.
Phase 3 Active not recruiting
NCT06498479 2024-10-16
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT06581380 2024-09-03
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
JenKem Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06526624 2024-07-30
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT04028050 2024-07-16
MAURIS
Hoffmann-La Roche
Phase 3 Completed